Skip to main content

In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC)

D. Minn.August 5, 2020No. 0:17-cv-01884
Facing something similar at work?Check your rights — free, private, no sign-up

Case Details

Nature of Suit — the legal category of the dispute
791 Labor: E.R.I.S.A.
Status — whether other courts must follow this ruling
Unknown

Related Laws

No specific laws identified for this ruling.

Claim Types

Breach of Contract

Outcome

The court denied plaintiffs' motion for class certification in this ERISA fiduciary breach action against pharmacy benefit managers regarding EpiPen rebates, finding that fiduciary status, breach, and injury could not be proven on a class-wide basis due to the individualized nature of thousands of ERISA plan terms.

What This Ruling Means

**EpiPen Price Case Against Pharmacy Benefit Managers Dismissed** This case involved workers and retirees who sued major pharmacy benefit managers (CVS Caremark, Express Scripts, Optum, and Prime Therapeutics) over high EpiPen prices. The plaintiffs claimed these companies, which manage prescription drug benefits for employer health plans, breached their duty to plan members by allowing EpiPen prices to skyrocket while potentially profiting from manufacturer rebates. The court dismissed the case by refusing to let it proceed as a class action lawsuit. The judge found that the workers couldn't band together in one large group because their individual health plans had different terms and rules. Since each plan was unique, the court would need to examine each person's situation separately to determine if the pharmacy benefit managers actually violated their duties. This made it impossible to resolve everyone's claims together in a single case. **What this means for workers:** This ruling makes it much harder for employees to challenge pharmacy benefit managers over drug pricing practices. Without the ability to join forces in class action lawsuits, individual workers face significant barriers when trying to hold these powerful companies accountable for high prescription drug costs.

This summary was generated to explain the ruling in plain English and is not legal advice.

Browse Related

Facing something similar at work?

Court rulings like this one are useful, but every situation is different. Take 2 minutes to see which laws may protect you — it's free, private, and no account is required to start.

This ruling information is sourced from public court records via CourtListener.com. Case outcomes, claim types, and summaries are extracted using AI analysis and may be incomplete or inaccurate. It is provided for informational and educational purposes only and does not constitute legal advice.

See something wrong, or named in this ruling and want it corrected or redacted? Request a correction.